Meloxivet
meloxicam
24
Medicinal product no longer authorised
authorised
Marketing authorisation holder: Eli Lilly and Company Limited Elanco Animal Health
Lilly House, Priestley Road Basingstoke
Hampshire RG24 9NL United Kingdom
Manufacturer for the batch release: Lusomedicamenta S.A.
Estrada Consiglieri Pedroso, 69 B Queluz de Baixo 2730-055 Barcarena
Portugal
no
Meloxivet 0.5 mg/ml oral suspension for dogs
One ml contains:
Meloxicam 0.5 mg
Sodium benzoate 1 mg
Medicinal
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.
Do not administer Meloxivet:
if your dog is pregnant or during lactation
if your dog is suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders
if your dog is hypersensitive (allergic) to the active substance or to any of the other ingredients.
if your dogs is less than 6 weeks of age
Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported.
These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
In very rare cases haemorrhagic diarrhoea, haematemisis, gastrointestinal ulceration and elevated liver
enzymes have been reported.
If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.
Dogs.
Oral use. To be administered with food .
longer
The suspension has to be given with the measuring syringe provided in the package. The syringe fits onto the bottle and has a kg-body weight scale which corresponds to the maintenance dose (i.e. 0.1 mg meloxicam/kg body weight). Thus for the first day, twice the maintenance volume will be required.
Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day. Treatment is to be continued once daily by oral administration (24 hour intervals) at a maintenance dose of 0.1 mg
meloxicam/kg body weight.
o
n
produ
Medicinal
Shake bottle well.
Push down and unscrew bottle top. Attach the dosing syringe to the bottle by gently pushing the end onto the top the bottle
ct
Turn the bottle
syringe upside down. Pull the plunger out until the black on the plunger corresponds to your dog’s bodyweight in kilograms.
Turn the bottle right
way up and with a twisting movement separate the dosing syringe from the bottle.
By pushing the
plunger in empty the contents of the syringe onto the food.
A clinical response is normally seen within 3 - 4 days. Treatment should be discontinued after 10 days at the latest if no clinical improvement is apparent.
For longer term treatment once clinical response has been observed (after 4 or more days), the dose of Meloxivet can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic musculo-skeletal disorders may vary over time.
Avoid introduction of contamination during use.
authorised
Particular care should be taken with regard to the accuracy of dosing. Please carefully follow the instructions of the veterinarian.
Not applicable.
Keep out of the reach and sight of children.
This veterinary medicinal product does not require any special storage conditions.
After each dose, the tip of the syringe should be wiped and the bottle cap screwed back on tightly. The syringe should be stored in the carton box in between uses.
Do not use after the expiry date stated on the label and carton after EXP. Shelf life after first opening the container: 6 months.
If side effects occur, treatment should be discontinued and the advice of a veterinarian should be sought. Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.
no
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Meloxivet must not be administered in conjunction with other NSAIDs or glucocorticosteroids.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously.
In the case of overdose symptomatic treatment should be initiated.
People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product.
Medicinal
In case of accidental ingestion, seek medical advice immediately and show this package leaflet or the label to the physician.
Any unused veterinary medicinal product or waste material derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Detailed information on this product is available on the website of the European Medicines Agency
10 ml presentation: amber glass bottle (type III) with polyethylene child resistant closure, polyethylene insert and an amber polypropylenedosing syringe.
authorised
30 ml presentation: amber glass bottle (type III) with polypropylene child resistant closure, polyethylene insert and an amber polypropylene dosing syringe.
Medicinal
no
Not all pack sizes may be marketed.
authorised
Marketing authorisation holder: Eli Lilly and Company Limited Elanco Animal Health
Lilly House, Priestley Road Basingstoke
Hampshire RG24 9NL United Kingdom
Manufacturer for the batch release: Lusomedicamenta S.A.
Estrada Consiglieri Pedroso, 69 B Queluz de Baixo 2730-055 Barcarena
Portugal
no
Meloxivet 1.5 mg/ml oral suspension for dogs
One ml contains:
Meloxicam 1.5 mg
Sodium benzoate 1 mg
Medicinal
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.
Do not administer Meloxivet:
if your dog is pregnant or during lactation
if your dog is suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders
if your dog is hypersensitive (allergic) to the active substance or to any of the other ingredients.
if your dogs is less than 6 weeks of age
Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported.
These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
In very rare cases haemorrhagic diarrhoea, haematemisis, gastrointestinal ulceration and elevated liver
enzymes have been reported.
If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.
Dogs.
Oral use. To be administered with food.
longer
The suspension has to be given with the measuring syringe provided in the package of the 30 and 150 ml pack size or with one of the two measuring syringes provided in the package of the 10 ml pack size. The syringe fits onto the bottle and has a kg-body weight scale which corresponds to the maintenance dose (i.e. 0.1 mg meloxicam/kg body weight). Thus for the first day, twice the maintenance volume will be required.
Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day. Treatment is to be continued once daily by oral administration (24 hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight.
o
ct
n
produ
Medicinal
Shake bottle well.
Push down and unscrew bottle top. Attach the dosing syringe to the bottle by gently pushing the end onto the top the bottle
Turn the bottle
syringe upside down. Pull the plunger out until the black on the plunger corresponds to your dog’s bodyweight in kilograms.
Turn the bottle right
way up and with a twisting movement separate the dosing syringe from the bottle.
By pushing the
plunger in empty the contents of the syringe onto the food.
A clinical response is normally seen within 3 - 4 days. Treatment should be discontinued after 10 days at the latest if no clinical improvement is apparent.
For longer term treatment once clinical response has been observed (after 4 or more days), the dose of Meloxivet can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic musculo-skeletal disorders may vary over time.
Avoid introduction of contamination during use.
Particular care should be taken with regard to the accuracy of dosing. Please carefully follow the instructions of the veterinarian.
authorised
The suspension of the 10 ml pack size could be administered using the smallest syringe for dogs less than 8 kg body weight (one graduation corresponding to 0.5 kg of body weight) or the largest syringe for dogs over than 8 kg body weight (one graduation corresponding to 2.0 kg of body weight).
Not applicable.
Keep out of the reach and sight of children.
This veterinary medicinal product does not require any special storage conditions.
After each dose, the tip of the syringe should be wiped and the bottle cap screwed back on tightly. The syringe should be stored in the carton box in between uses.
Do not use after the expiry date stated on the label and carton after EXP. Shelf life after first opening the container: 6 months.
no
If side effects occur, treatment should be discontinued and the advice of a veterinarian should be sought. Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Meloxivet must not be administered in conjunction with other NSAIDs or glucocorticosteroids.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously.
In the case of overdose symptomatic treatment should be initiated.
Medicinal
People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show this package leaflet or the label to the physician.
Any unused veterinary medicinal product or waste material derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Detailed information on this product is available on the website of the European Medicines Agency
10 ml presentation: amber glass bottle (type III) with polyethylene child resistant closure, polyethylene insert and clear polypropylene dosing syringe. Two measuring syringes are provided.
authorised
30 ml and 150 ml presentation: amber glass bottle (type III) with polypropylene child resistant closure, polyethylene insert and clear polypropylene dosing syringe.
Medicinal
no
Not all pack sizes may be marketed.